$CELG Company News Is the next Cisco out there? 3:24

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2014 at 12:51 PM

$CELG Company News

Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane

Agios, Celgene to Start Approval Studies of Cancer Metabolism Drug in 2015 20 min ago - TheStreet.com
Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 9:15 a.m. Dec. 6, 2014 - TheStreet.com
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences 12:18 p.m. Dec. 5, 2014 - TheStreet.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14) 4:36 a.m. Dec. 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 2:00 p.m. Dec. 4, 2014 - TheStreet.com
Acetylon Begins Phase 2 Study Of Ricolinostat With Pomalyst 8:08 a.m. Dec. 4, 2014 - benzinga.com
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
'Mad Money' Lightning Round: You're on Your Own With Tesla 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Cramer's Lightning Round - Power To The PPL (12/2/14) 5:46 a.m. Dec. 3, 2014 - Seeking Alpha
Cramer's Mad Money - Deckers Is About More Than Just Uggs (12/2/14) 5:33 a.m. Dec. 3, 2014 - Seeking Alpha
‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound? 5:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners 8:21 p.m. Dec. 2, 2014 - TheStreet.com
Top Funds Gobble Up Tech And Medical Stocks 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily

Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Gold Corp. Gears Up for Key October Event

Marking Calendars for the Emerging Growth Showdown There's nothing quite like the buzz leading up to an event where you know someone’s either gonna make a splash or barely leave a ripple. U.S. Gold Corp. is drawing some attention ahead of the Emerging Growth Conference on October 29, 2026. This ain't just any corporate dog-and-pony show—it's a chance for the Gold...

Firmable Climbs G2 Ranks in Sales Intelligence

Success stories aren't written overnight, and Firmable's recent leap in G2's rankings proves that point. This AI-native B2B sales powerhouse has muscled its way from #8 to #4 on the global Momentum Grid for Sales Intelligence, marking a dramatic rise that's hard to ignore. Being recognized at this level shows the company's on a solid path, but let's see what makes this...

North Island Credit Union Eases Student Access to Banking

Breaking Down Barriers with Student Banking Services Stumble into any financial setup these days, and you'll hear the same refrain: young people need more access to banking. North Island Credit Union seems to have taken that idea to heart, landing a national Bank On certification for their Student Checking account. It ain't just any badge; it's the mark of reliability,...

Gargle App Elevates Dental Marketing Transparency, ROI Focus

Dentists Finally See the Whole Picture with Gargle's App Out in Lehi, Utah, there's a little tech shakeup courtesy of Gargle—a name some might squint at if they haven't been following dental-focused digital marketing. Now, with their latest move, the Gargle App, we're talking about pulling back the curtain and giving dental practices a clear view of their marketing...

Enertech's New Moves Aim to Make Geothermal Mainstream

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Northeast Indiana Bancorp Shows Solid Third Quarter Gains

Holding Steady in a Shaky Market In a market often rocked by turbulence, it seems Northeast Indiana Bancorp, Inc. has found a decent footing to stand on. Announcing their third-quarter results for 2026, they’ve posted net income of $1.991 million, showcasing a neat jump from the $1.793 million in the same period last year. Not bad at all for the parent company of First...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

New Research Awards Target Drug Resistance in Cancers

Well, this is a breath of fresh air in the lung cancer scene, let's talk about some promising news for those battling RET-positive cancers. The LUNGevity Foundation and RETpositive have handed out some well-deserved awards to researchers aiming to crack the stubborn nut of drug resistance in RET-positive cancer therapies. Changing the Game for RET-positive Cancer RET gene...

Technical Deep Dive into HONOR X9e Pro's Durability

Rethinking Smartphone Power HONOR's latest device, the X9e Pro, flaunts an 11,000mAh battery—stuck it right behind a neat cover without making the thing feel like a brick. You'd think with a battery that big, they’d have to hire bodybuilders to lift it, but nope. At 8.08mm thick and weighing just 203g, this phone bucks the bulk. They’ve squeezed the power of a power...

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...